CS
ACET icon

Candriam SCA’s Adicet Bio ACET Stock Holding History

Candriam SCA’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-44,743
Closed -$1.74M – 658
2023
Q2 		$1.74M Sell
44,743
-32,180
-42% -$2.84M 0.01% 522
2023
Q1 		$6.53M Hold
76,923
– – 0.05% 317
2022
Q4 		$11M Sell
76,923
-13,834
-15% -$3.45M 0.07% 255
2022
Q3 		$20.6M Buy
90,757
+10,533
+13% +$2.67M 0.15% 160
2022
Q2 		$18.7M Buy
+80,224
New +$17.6M 0.15% 147

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Candriam SCA's ACET Position: Q3 2023 in Review

Candriam SCA sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 44,743 shares — an estimated $1.74M sold.

Candriam SCA first reported a position in ACET in Q2 2022 and held it in 5 quarters. The position peaked at $20.6M in Q3 2022. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

  • Candriam SCA reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
  • Candriam SCA sold 44,743 Adicet Bio shares in Q3 2023, an estimated $1.74M.
  • Candriam SCA first reported a position in Adicet Bio in Q2 2022 and held it in 5 quarters.
  • Candriam SCA's Adicet Bio position peaked at $20.6M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.